18:35:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
PCI Biotech Holding är en biofarmaceutiskt koncern, där största delen av verksamheten bedrivs inom dotterbolaget PCI Biotech. Koncernen bedriver idag verksamhet inom utveckling av terapeutiska produkter baserat på den egenutvecklade PCI tekniken. Lösningarna är avsedda att användas vid behandling utav cancerpatienter. PCI Biotech grundades ursprungligen 2000 som ett dotterbolag till Photocure och har idag sitt huvudkontor i Oslo.

Kalender

2022-11-23 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning PCIB 0.00 NOK
2022-05-25 Årsstämma 2022
2022-05-11 Kvartalsrapport 2022-Q1
2022-02-18 Bokslutskommuniké 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-31 Ordinarie utdelning PCIB 0.00 NOK
2021-05-28 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-05-28 Ordinarie utdelning PCIB 0.00 NOK
2020-05-27 Årsstämma 2020
2020-05-06 Kvartalsrapport 2020-Q1
2020-02-26 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-31 Ordinarie utdelning PCIB 0.00 NOK
2019-05-29 Årsstämma 2019
2019-05-08 Kvartalsrapport 2019-Q1
2019-02-13 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-30 Ordinarie utdelning PCIB 0.00 NOK
2018-05-29 Årsstämma 2018
2018-05-08 Kvartalsrapport 2018-Q1
2018-03-19 Bokslutskommuniké 2017
2017-11-28 Kvartalsrapport 2017-Q3
2017-08-29 Kvartalsrapport 2017-Q2
2017-05-30 Ordinarie utdelning PCIB 0.00 NOK
2017-05-29 Årsstämma 2017
2017-05-16 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-12-08 Extra Bolagsstämma 2016
2016-11-22 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-20 Ordinarie utdelning PCIB 0.00 NOK
2016-05-19 Årsstämma 2016
2016-05-03 Kvartalsrapport 2016-Q1
2016-02-09 Bokslutskommuniké 2015
2015-11-17 Kvartalsrapport 2015-Q3
2015-08-18 Kvartalsrapport 2015-Q2
2015-05-13 Ordinarie utdelning PCIB 0.00 NOK
2015-05-12 Årsstämma 2015
2015-05-12 Kvartalsrapport 2015-Q1
2015-02-24 Bokslutskommuniké 2014
2014-11-18 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-05-14 Ordinarie utdelning
2014-05-13 Kvartalsrapport 2014-Q1
2014-05-13 Årsstämma 2014
2014-02-25 Bokslutskommuniké 2013
2013-10-29 Kvartalsrapport 2013-Q3
2013-08-20 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning
2013-05-06 Årsstämma 2013
2013-04-30 Kvartalsrapport 2013-Q1
2013-03-21 Bokslutskommuniké 2012
2012-10-30 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-05-08 Kvartalsrapport 2012-Q1
2012-04-26 Ordinarie utdelning
2012-04-25 Årsstämma 2012
2012-02-07 Bokslutskommuniké 2011
2011-11-01 Kvartalsrapport 2011-Q3
2011-08-23 Kvartalsrapport 2011-Q2
2011-05-10 Kvartalsrapport 2011-Q1
2011-04-14 Ordinarie utdelning
2010-10-25 Kvartalsrapport 2010-Q3
2010-08-23 Kvartalsrapport 2010-Q2
2010-05-19 Ordinarie utdelning
2010-05-18 Årsstämma 2010
2010-04-26 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-26 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-29 Kvartalsrapport 2009-Q1
2022-05-04 15:10:00

Oslo, Norway, 4 May 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's Q1 2022 interim report on Wednesday 11 May 2022, 08:30am – 09:30am CEST (local time).

The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session.

PCI Biotech’s Q1 2022 interim report will be released on 11 May 2022 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com.

For further information, please contact:
Ronny Skuggedal, CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech        
PCI Biotech is a biopharmaceutical clinical stage development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The company’s lead programme fimaVacc aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. Enhancement of relevant immune responses with protein- and peptide-based vaccines were successfully demonstrated in humans through an extensive Phase I study in healthy volunteers and a Phase II study is in planning with the aim to demonstrate enhancement of immunotherapy for treatment of solid tumours. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com                
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo            

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.